Business
Issue of Equity
Issue of Equity.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \n \n 8 February 2023\n \n \n \n \n \n \n \n \n \n Scancell Holdings plc\n \n \n \n (\"Scancell\" or the \"Company\")\n \n \n \n \n \n \n Exercise of Share Options and Admission of New Ordinary Shares\n \n \n \n \n \n \n \n \n \n \n \n \n \n Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies, today announces that it has issued 3,184,630 new ordinary shares of 0.1p each in the share capital of the Company (\"Ordinary Shares\"), pursuant to the exercise of share options by IchorMedical Systems Inc.at an exercise price of 4.5p per Ordinary Share.\n \n \n \n \n \n An application for the admission of the 3,184,630 Ordinary Shares to trading on AIM (\"Admission\") has been made. It is expected that Admission will become effective on or around 13 February 2023.\n \n \n \n \n \n The new Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares. The total number of Ordinary Shares in issue following Admission will be 818,403,461. This number may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.\n \n \n \n \n \n \n \n \n \n \n For further information, please contact:\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Scancell Holdings plc\n \n \n \n \n \n +44 (0) 20 3727 1000\n \n \n \n \n \n \n Dr Jean-Michel Cosséry, Non-Executive Chairman\n \n \n \n \n +44 (0) 20 7886 2500\n \n \n \n \n \n \n Professor Lindy Durrant, CEO\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Stifel Nicolaus Europe Limited\n \n (Nominated Adviser and Joint Broker)\n \n \n \n \n +44 (0) 20 7710 7600\n \n \n \n \n \n \n Nicholas Moore/Samira Essebiyea/William Palmer-Brown (Healthcare Investment Banking)\n \n \n \n \n \n \n \n \n \n \n \n \n \n Nick Adams/Nick Harland (Corporate Broking)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Panmure Gordon (UK) Limited\n \n (Joint Broker)\n \n \n \n \n +44 (0) 20 7886 2500\n \n \n \n \n \n \n Freddy Crossley/Emma Earl (Corporate Finance)\n \n \n \n \n \n \n \n \n \n \n \n \n \n Rupert Dearden (Corpora...